Bionano Genomics, Inc. announced the publication of a peer-reviewed study from Sanford Burnham Prebys Medical Discovery Institute describing the use of optical genome mapping (OGM) to detect genomic alterations introduced by gene editing technologies such as transposons, lentiviral transduction, and CRISPR-Cas9-mediated locus insertion. The results of this study have already been presented and published in Molecular Therapy - Methods & Clinical Development. The study suggests that OGM could serve as a valuable tool for quality control of genome integrity during the pre-clinical and clinical development of gene editing therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bionano Genomics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9648585-en) on February 04, 2026, and is solely responsible for the information contained therein.